Loading clinical trials...
Loading clinical trials...
Magnetic nanoparticles, coated with human leukocyte antigens (HLA) to capture anti-HLA antibodies with donor specificity (donor-specific antibodies, DSA), will be tested ex-vivo.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University of Zurich
NCT04128189 · Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure, and more
NCT06056102 · Kidney Transplant, Kidney Failure, and more
NCT06343727 · Kidney Failure, Frailty, and more
NCT06972069 · Kidney Failure, Transplant Recipient (Kidney), and more
NCT06660277 · Chronic Kidney Disease Requiring Hemodialysis, End-Stage Kidney Disease (ESKD), and more
University Hospital Zurich, Division of Anaesthesiology
Zurich, Canton of Zurich
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions